Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 246

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts

Open access
Díaz-Lagares, Cándido, Croca, Sara, Sangle, Shirish, Vital, Edward M., Catapano, Fausta, Martínez-Berriotxoa, Agustín, García-Hernández, Francisco, Callejas-Rubio, José-Luis, Rascón, Javier, D'Cruz, David, Jayne, David, Ruiz-Irastorza, Guillermo, Emery, Paul, Isenberg, David, Ramos-Casals, Manuel, Khamashta, Munther A. · 2012 · Autoimmunity Reviews

Abstract

OBJECTIVE To present a pooled analysis of the efficacy of rituximab from European cohorts diagnosed with biopsy-proven lupus nephropathy (LN) who were treated with rituximab. METHODS Consecutive patients with biopsy-proven LN treated with rituximab in European reference centers were included. Complete response (CR) was defined as normal serum creatinine with inactive urinary sediment and 24-hour urinary albumin <0.5 g, and partial response (PR) as a >50% improvement in all renal parameters that were abnormal at baseline, with no deterioration in any parameter. RESULTS 164 patients were included (145 women and 19 men, with a mean age of 32.3 years). Rituximab was administered in combination with corticosteroids (162 patients, 99%) and immunosuppressive agents in 124 (76%) patients (cyclophosphamide in 58 and mycophenolate in 55). At 6- and 12-months, respectively, response rates were 27% and 30% for CR, 40% and 37% for PR and 33% for no response. Significant improvement in 24-h proteinuria (4.41 g. baseline vs 1.31 g. post-therapy, p=0.006), serum albumin (28.55 g. baseline to 36.46 g. post-therapy, p<0.001) and protein/creatinine ratio (from 421.94 g/mmol baseline to 234.98 post-therapy, p<0.001) at 12 months was observed. A better response (CR+PR) was found in patients with type III LN in comparison with those with type IV and type V (p=0.007 and 0.03, respectively). Nephrotic syndrome and renal failure at the time of rituximab administration predicted a worse response (no achievement of CR at 12 months) (p<0.001 and p=0.024, respectively). CONCLUSION Rituximab is currently being used to treat refractory systemic autoimmune diseases. Rituximab may be an effective option for patients with lupus nephritis, especially those refractory to standard treatment or who experience a new flare after intensive immunosuppressive treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.autrev.2011.10.009

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 246

Metadata

Authors
Díaz-Lagares, C., Croca, S., Sangle, S., Vital, E. M., Catapano, F., Martínez-Berriotxoa, A., García-Hernández, F., Callejas-Rubio, J.-L., Rascón, J., D'Cruz, D., Jayne, D., Ruiz-Irastorza, G., Emery, P., Isenberg, D., Ramos-Casals, M., & Khamashta, M. A.
Venue
Autoimmunity Reviews
Publisher
Elsevier BV
Published
2012-03
Volume
11
Issue
5
Pages
357-364
ISSN
1568-9972 (ISSN-L)
OpenAlex
W2000054082
Cited by
246
References
2
FWCI
17.28
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. https://app.cochat.ai/papers/10.1016/j.autrev.2011.10.009
The paper
Díaz-Lagares, C., Croca, S., Sangle, S., Vital, E. M., Catapano, F., Martínez-Berriotxoa, A., García-Hernández, F., Callejas-Rubio, J.-L., Rascón, J., D'Cruz, D., Jayne, D., Ruiz-Irastorza, G., Emery, P., Isenberg, D., Ramos-Casals, M., & Khamashta, M. A. (2012). Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmunity Reviews. https://doi.org/10.1016/j.autrev.2011.10.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.